Deborah Wild: Thrilled to See GeneVentiv Selected for The NIH NHLBI Catalyze Program
Deborah Wild, CEO, Executive Board Member, and Leadership Coach, reposted from Damon Race on LinkedIn:
”Thrilled to see GeneVentiv selected for the NIH NHLBI Catalyze Program — a strong endorsement of both the science and our team. The company’s approach to treating all hemophilia A patients with a single gene therapy holds tremendous promise.
As many of you may know, the treatment of hemophilia is very important to me. Happy to be part of the team.”
Damon Race, President and CEO of GeneVentiv Therapeutics, shared on LinkedIn:
”Proud moment for GeneVentiv Therapeutics!
Our team has been selected into the NIH NHLBI Catalyze Program, which will fund the GLP toxicology study required for our IND submission of GENV-HEM — our one-time gene therapy designed to treat all hemophilia A patients, including those with inhibitors.
This highly competitive NIH program is one of the strongest scientific and regulatory signals of confidence a pre-IND company can receive — reflecting both the strength of our data and the rigor of our development plan. By funding the most capital-intensive portion of IND-enabling work, Catalyze support increases capital efficiency, allowing investor funds to focus on valuation-driving activities — including IND preparation, regulatory engagement, and readiness for our Phase I/II clinical trial.
Execution of the GLP toxicology study will follow dose determination from our upcoming canine efficacy and safety study, scheduled to begin in January 2026, with initial data expected in late Q1 2026. Together with our ongoing NHLBI SBIR award, which supports assay development and canine studies, the Catalyze award provides broad, non-dilutive support across efficacy, safety, and regulatory preparation — a rare position for a preclinical gene therapy company.
Grateful for the continued partnership of our scientific, regulatory, and NIH collaborators as we move GENV-HEM toward the clinic and advance our gene-editing program for Pompe disease.
Read the press release here.”
Stay updated with Hemostasis Today.
-
Jan 12, 2026, 14:46A Behcet Disease with Aortic Thrombosis: Alexandru Stieber Shares A Peculiar Case
-
Jan 12, 2026, 04:51Coronary Microvascular Dysfunction and HFpEF․ Prognostic Importance and Therapeutic Insights
-
Jan 12, 2026, 04:16Wolfgang Miesbach on VTE and Cancer: A 20-Year Signal That Can’t Be Ignored
-
Jan 12, 2026, 03:54Francine Freitas Fernandes on Transvaginal US for Pelvic Venous Disorders
-
Jan 12, 2026, 02:58Jara Garcia Ugaldebere Shares STORM-PE Results: Thrombectomy Plus Anticoagulation for Acute High-Risk PE
-
Jan 12, 2026, 02:54Discover the New Blood Project․ Enhanced Search, Browsing, and Learning Resources
-
Jan 12, 2026, 02:54Can Preoperative Iron Status Predict Severe Anemia After Bariatric Surgery?
-
Jan 12, 2026, 02:27Bryce Kerlin to Impact of Advanced Hemostasis/Thrombosis Fellowship Training at Haemophilia Publication
-
Jan 12, 2026, 02:21Martin Haluzík on Compariosn of Cardiovascular Outcomes Between Semaglutide and Dulaglutide Therapies